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Abstract: Modern medicine is characterized by a continuous genesis of evidence making 
it very difficult to translate the latest findings into a better clinical practice. Clinical practice 
guidelines (CPG) emerge to provide clinicians evidence-based recommendations for their daily 
clinical practice. However, the high number of existing CPG as well as the usual differences in 
the given recommendations usually increases the clinician’s confusion and doubts. It has appar-
ently been the case for the 2013 American College of Cardiology/American Heart Association 
(ACC/AHA) Guideline on the Treatment of Blood Cholesterol. These CPG proposed new 
and controversial concepts that have usually been considered an antagonist shift respective to 
European CPG. The most controversial published proposals are: 1) to consider evidence just 
from randomized clinical trials, 2) creation of a new cardiovascular (CV) risk calculator, 3) to 
consider reducing CV risk instead of reducing low-density lipoprotein cholesterol (LDLc) as 
the target of the treatment, and 4) consideration of statins as the only drugs for treatment. A 
deep analysis of the 2013 American College of Cardiology/American Heart Association CPG 
and comparison with the European ones show that from a practical and clinical point of view, 
there are more similarities than differences. To further help clinicians in their daily work, in 
the present globalized world, it is time to discuss and adopt a mutually agreed upon document 
created by both sides of the Atlantic. Probably it is not a short-term solution. Meanwhile, taking 
advantage of the similarities, the recommended practical attitude for the daily clinical practice 
should be based on 1) early detection of people with increased CV risk promoting the use of 
validated local scales, 2) reinforce the mainstream importance of nonpharmacological treatment, 
and 3) need for periodically monitoring response with analytical parameters (LDL or non-high-
density lipoprotein cholesterol) and global CV risk estimation. Technological solutions such 
as the big data technology could help to obtain high-quality evidence in an intermediate term. 
Keywords: dyslipidemia, statins, cardiovascular risk, clinical practice guidelines
Introduction 
The ultimate objective of the clinician is to apply the best evidence to his/her daily 
clinical practice, but some difficulties hinder this. Because modern medicine is in 
a continuous evolution due to the increasing amount of new evidence, it is quite 
difficult for clinical physicians to remain up-to-date. When consulting some expert 
opinions in order to clarify doubts, the opinion as well as the potential applicability 
of the same data varies depending on the consulted publication. Because trials study 
specific populations in specific scenarios, it is not unusual for physicians to find that 
the problem to be clarified has never been studied or that the existing evidence is too 
weak to establish a clear recommendation.1,2
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Applying evidence-based medicine principles,3 clinical 
practice guidelines (CPG) try to solve the aforementioned 
problems. They are the written result of reviewing the 
evidence to translate it to daily clinical practice to guide 
physicians in making decisions based on the best available 
evidence. However, this is not always the case as can be 
demonstrated by the unjustified high number of existing 
CPG,4 each with different recommendations. For example, 
currently in the United States, there are more than 2,500 
CPG.5 On the other hand, different studies have demonstrated 
low quality,6–8 as illustrated for example by Ferket et al,6 in 
whose manuscript, after initial consideration of nearly 1,900 
CPG, only 17 of the 27 finally included were considered with 
“considerable rigor.” 
Part of the proliferation of CPG could be explained by 
the existence of interests outside the strictly scientific and 
health care fields. This is a complex element to analyze, 
because the majority of CPG have little information regard-
ing conflict of interests. About three-fifths of the existing US 
CPG are issued by a medical society or a professional asso-
ciation, which leads to negative concerns regarding conflict 
of interests and criteria for the election of experts.5,7,8 In the 
previously mentioned manuscript by Ferket et al,6 only 16 of 
the 27 CPG included reported authors’ conflicts of interest. 
Another factor to be considered and corrected to explain the 
high number of existing CPG and the high heterogeneity in 
their final recommendations is related to industry pressure 
as well as the medical scientific associations who needs to 
be present in the media.9
To solve this situation, different potential solutions exist.10 
Some authors think that the solution is to use just the best 
available evidence, which in their opinion is that obtained 
from randomized clinical trials (RCTs). But the generaliza-
tion of the results from RCT, is difficult and always needs 
an important subjective component of interpretation.4,10 A 
direct application can also be harmful because CPG do not 
present recommendations in terms of benefits, harms, and 
costs, but just in terms of efficacy and almost exclusively 
referred to pharmacological treatments. As recognized by 
evidence-based medicine itself, a wider point of view is 
necessary by including all kinds of information as the only 
way to give reasonable answers to clinical questions.4,5 This is 
the reason why in recent years it has been widely recognized 
that it is necessary to incorporate other variables apart from 
efficacy, such as patients’ preferences and hopes in the so-
called shared decision making.11 As recognized by all recent 
CPG, understanding the limitations of available evidence 
and awareness of additional published guidelines will help 
practitioners make personalized decisions with patients and 
enhance the clinician–patient discussion.12,13
The publication of the so-called Adult Treatment Panel 
(ATP) IV was longtime overdue by general physicians as an 
actualization of the previous guideline in 2002; probably the 
most worldwide used CPG on dyslipidemia.14 This document 
has advocated for new concepts for the management of dys-
lipidemia, promoting some controversy.13 Since its publica-
tion, a lot of different arguments have been published against 
and in favor of these new concepts. In general, the new 2013 
American College of Cardiology/American Heart Associa-
tion (ACC/AHA) CPG15 have been considered antagonistic 
when compared with the European CPG16–18 points of view.
In the present review, the new ACC/AHA guidelines15 
are compared with the “European” ones, considering those 
published by the European Society of Cardiology/European 
Atherosclerosis Society (ESC/EAS) in 2011 and 201216,17 and 
those by the British National Institute for Health and Care 
Excellence (NICE),18 because of some differences with the 
ESC/EAS points of view as well as its worldwide recogni-
tion. First, those considered the most important controversial 
points among the new American and the European guidelines 
are analyzed. In the second part, those points that could be 
considered as consensual are also analyzed. Finally, some 
potential realistic actions are proposed to contribute to the 
reduction of actual discrepancies among CPG and the second-
ary confusion among clinical physicians. All the analyses and 
comments are made from a practical point of view trying to 
answer clinical daily questions.
Dissimilarities 
On November 12, 2013, the ACC/AHA issued new clinical 
guidelines on cardiovascular (CV) disease risk assessment19 
and cholesterol management.15 Since its presentation, a great 
controversy has emerged because these CPG proposals have 
represented a shift in the management of dyslipidemia.20,21 
In the medical literature, the reactions have usually been 
negative when compared with other CPG, not only from the 
United States,22 but also from other countries and regions 
of the world,23 especially when considering the ESC/EAS 
guidelines.24 However, most recent publications recognize 
the limitations and gaps of the new American guidelines,25 
reinforce the similarities, and propose some potential solu-
tions to achieve a consensus.26,27
Methodological differences can explain a great part of the 
dissimilarities. The main methodological difference is that 
2013 ACC/AHA guidelines solely consider RCT as a valid 
source of evidence.15,22 On the contrary, both the ESC/EAS16,17 
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and the NICE18 CPG consider that other sources need to be 
included as the only way to translate evidence to clinical 
practice.28 The ESC/EAS16,17 also indicates the possibility of 
evidence obtained from an RCT to be considered as having 
low quality, as well as the possibility of evidence other than 
RCT-obtained evidence to create a high strength recommen-
dation because of the methodological quality of the study or 
its congruency with the general knowledge. In accordance 
with this approach, the International Atherosclerosis Society 
(IAS) CPG29 say that “allowing RCTs to dominate guideline 
development largely restricts them to drug recommendations; 
reliable RCTs for lifestyle therapies are few … finally, RCTs 
are mostly sponsored by the pharmacological industry. They 
are designed primarily to obtain regulatory registration, not 
to answer critical questions in clinical intervention. The IAS 
panel recognized the enormous fund of useful information 
provided by RCT; but it also has placed RCT in the context of 
epidemiological and genetic findings.” Although it has been 
underscored as a main dissimilarity that ACC/AHA CPG15 
consider RCT as the only source of qualified evidence, when 
reinforcing the cornerstone importance of nonpharmacologi-
cal treatment, these guidelines recognize that evidence is very 
scarce and based only on surrogate outcomes.
Another methodological limitation for all the CPG con-
sidering the recommendations obtained from RCT are that 
they critically depend on which publications are considered. 
It is obvious the effect of only just including publications 
since 1995 by the ACC/AHA guideline30, while the Euro-
pean ones include those since the sixties.16–18 This can also 
be applied related to the recent publication of Improved 
Reduction of Outcomes: Vytorin Efficacy International Trial 
(IMPROVE-IT),31 and Prevención con Dieta Mediterránea 
(PREDIMED),.32 two recent big RCTs that give new evidence 
to be considered for all CPG on dyslipidemia but are not 
included in any because both the studies have been published 
later. In the same way, each CPG has its own criteria to select 
the source of evidence. Finally, although they all establish the 
strength of the recommendations according to the GRADE 
system,33 the final expression of the recommendations is not 
the same, contributing to the actual confusion of the clinicians. 
This is quite similar for the ACC/AHA15 and ESC/EAS16,17 
guidelines; meanwhile the recommendations in the NICE18 
CPG are expressed with the words “offer” and “consider.” 
The second main dissimilarity is referred to the defini-
tion of the persons in primary prevention to be treated. For 
the identification of patients at risk, all the actual CPG use 
multifactorial CV estimators (Table 1). The new ACC/AHA 
guidelines15 have proposed a new Pooled Cohort Equations 
Risk Calculator (PCERC) based on seven major National 
Heart, Lung, and Blood Institute-funded cohort studies for 
US population to predict 10-year risk of nonfatal myocardial 
infarction, fatal coronary heart disease, and nonfatal or fatal 
stroke.19,34 Both the ESC/EAS16,17 and the NICE18 guidelines 
have their own calculator: the so-called Systematic Coronary 
Risk Evaluation Project (SCORE) 36 and the QRISK2.37,38 
A difference with the QRISK2 calculator, obtained from 
electronic health records of general practice attendees in the 
United Kingdom, is that the other two have been obtained 
from European and American cohorts of prospective stud-
ies. For all the calculators, the risk factors considered are 
the traditional ones (sex, blood pressure, age, smoking, and 
lipids), and all are estimators of absolute risk, although the 
2012 ESC/EAS has a specific tool for younger people to 
estimate relative risk.16 In this respect, all the CPGs comment 
on the necessity to estimate all-life risk instead of the actual 
usual period of 10 years, and, as previously proposed by the 
IAS,29 in 2010 a version of the QRISK2 calculator estimating 
all-life CV risk was published.38
The main criticism to be made when analyzing the 
PCERC is that overestimates about 75%–150% the indi-
vidual CV risk. This overestimation can be due to the inclu-
sion of stroke as well as the adoption of a lower threshold 
for the definition of increased risk (7.5% instead of 10%).45 
The immediate consequence is the increase in the number 
of people to be treated.46,47 Compared with the ATP III 
CPG,14 the new guideline would increase the number of 
US adults eligible for statin therapy from 37.5% to 48.6%. 
When applying PCERC for primary prevention in people at 
the ages 60–75 years, the percentage to be treated increases 
from 30.4% to 87.4% among men and from 21.2% to 53.6% 
among women, with the main determinant of increased 
risk being hypertension.46 When PCERC is applied to 
European populations, there is a similar impact (Table 2).47 
An evident explanation for the increase is that US popula-
tion has a higher CV risk than European, but it would not 
explain the difference when applying ATP III calculator,14 
pointing to the fact that probably the incremental effect 
is a consequence of the lower threshold in PCERC. The 
“global population statinization” derived by the application 
of the PCERC has two immediate consequences. First, a 
marked economic impact, although in the opinion of the 
authors of the ACC/AHA CPG,15 this could be balanced by 
an incremental use of generic statins. In this respect, it is 
interesting to know that ESC/EAS16,17 CPG do not analyze 
the economic impact of their recommendations and that 
only for the NICE guidelines18 this aspect is considered in 
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Table 1 Main actual disposable CV risk calculators and their general characteristics
PCERC19 Frmingh35 SCORE36 QRISK237, 38 ASSIGN39 Lloyd-Jones40 PROCAM41
CPG 2013 ACA/AHA15 ATP III14 ESC/EAS15,16 NICE18 SIGN43 IAS29 ITFPCD44
Data source 7 NHLBI -funded 
cohort studies for 
US population 
Prospective 
Framingham 
Heart and 
Offspring 
studies
12 pooled 
prospective 
studies from 
11 European 
countries
QResearch 
electronic database
SHHEC 
prospective study
Framingham Heart 
Study participants free 
of CV disease
Prospective 
study
Population African-American 
or White 
participants with 
≥12 years of 
follow-up 
US general 
population 
volunteers 
from 
Framingham, 
MA, USA
Random samples 
from general 
population, some 
occupational 
cohorts
Health records of 
general practice 
attendees
General population 
in Scottish 
MONICA and the 
Scottish Heart 
Health studies
US general population 
volunteers from 
Framingham, MA, USA
Healthy male 
employees 
in Münster 
(Germany)
Sample size Whites:
9,098 ♂ 
11,240 ♀ 
African-American:
1,647 ♂
2,641 ♀
3,969 ♂
4,522 ♀
117,098 ♂
88,080 ♀
2.29 million 
(QRISK2)
6,540 ♂
6,757 ♀
564 ♂
4,362 ♀
18,460 ♂
8,515 ♀
Age (years) 40–79 30–75 40–65 35–74 30–74 50 20–75
Calculates Sex- and race-
specific 10-year 
risk for fatal CHD, 
nonfatal MI, all 
stroke 
Latest version: 
10-year risk of 
CV events
10-year risk of CV 
mortality
Version for 
relative risk for 
<40 years
10-year risk of CV 
events
All-life CV risk 
version38
10-year risk of CV 
events
Total CV morbidity by 
age 80 years, from age 
50 years
10-year risk 
of coronary 
and cerebral 
ischemic 
events
Included 
variables
Age, Tc, HDLc, 
SBP, DM, current 
smoking status
Sex, age, Tc, 
HDLc, SBP, 
smoking, DM, 
HTd 
Sex, age, Tc or 
Tc/HDLc, SBP, 
smoking
Versions for 
high- and low-risk 
countries
Sex, age, Tc/HDLc, 
SBP, smoking, DM, 
social deprivation, 
family history, BMI, 
HTd, ethnicity, 
comorbidity
Sex, age, Tc, HDLc, 
SBP, number of 
cigarettes, DM, 
social deprivation, 
family history of 
CHD
Tc, smoking, BP, DM Age, sex, 
LDLc, 
HDLc, DM, 
smoking, SBP
Thresholds + <5%
++ 5–7.4%
+++ ≥7.5%
+ <5 %
++ 5–20%
+++ >20%
+ <1%
++ 1–4% 
+++ 5–10%
++++ >10%
+ 5% 
++ 10% 
+++ 15%
++++  ≥20%
+ <10%
++ 10–19%
+++ ≥20%
+ <15%
++ 15–29%
+++ 30–44%
++++ >45%
+++ >53 
(>20%)
Notes: +, low CV risk; ++, moderate CV risk; +++, high CV risk; ++++, very high CV risk. Data based on Cooney et al.44
Abbreviations: ACA/AHA, American College of Cardiology/American Heart Association; ASSIGN, Assessing cardiovascular risk using SIGN guidelines to ASSIGN 
preventive treatment; ATP III, Adult Treatment Panel III; BMI, Body mass index; BP, blood pressure; CHD, coronary heart disease; DM, diabetes mellitus; ESC/EAS, European 
Society of Cardiology/European Atherosclerosis Society; Frmingh, Framingham score; HDLc, high-density lipoprotein cholesterol; HTd, having antihypertensive drugs; IAS, 
International Atherosclerosis Society; ITFPCD, International Task Force for Prevention of Coronary Disease; MI, myocardial infarction; NICE, National Institute for Health 
and Care Excellence; PCERC, Pooled Cohort Equations Risk Calculator; SBP, systolic blood pressure; SCORE, Systematic Coronary Risk Evaluation; SHHEC, Scottish Heart 
Health Extended Cohort; SIGN, Scottish Intercollegiate Guidelines Network; Tc, Total cholesterol; CV, cardiovascular; LDLc, low-density lipoprotein cholesterol; CPG, 
clinical practice guidelines; NHLB, National Heart, Lung, and Blood Institute; MONICA, multinational monitoring of trends and determinants in cardiovascular disease. 
a specific and detailed way, concluding that the  disposable 
information is very scarce to analyze the effectiveness of 
dyslipidemia management, although enough to establish 
that the cost-effective treatments are atorvastatin 20 and 80 
mg/day for primary and secondary prevention, respectively. 
The second consequence of a generalized use of statins is the 
increased risk for toxicity. It is an important issue consider-
ing that the most important increase in adult population to 
be treated affects older people, with higher susceptibility 
for secondarisms and a considerable portion of indications 
in the absence of hyperlipidemia.48 However, some authors 
argue that the higher sensitivity of PCERC allows to cover 
more adequately those patients who will have a CV event, 
because of its better predictive capacity.49
Table 2 Proportion of participants of the Rotterdam study to 
be treated with statins applying different actual guidelines for the 
management of dyslipidemia criteria
Guideline ♂ ♀
2013 ACC/AHA15 96.4% 
(95% CI, 95.4%–97.1%)
n=1,825
65.8% 
(95% CI, 63.8%–67.7%) 
n=1,523 
2012 ESC/EAS16,17 66.1%
(95% CI, 64.0%–68.3%)
n=1,253 
39.1%
(95% CI, 37.1%–41.2%)
n=906
2002 ATP III14 52.0% 
(95% CI, 49.8%–54.3%)
n=985 
35.5%
(95% CI, 33.5%–37.5%)
n=821
Note: Data from Kavousi et al.47
Abbreviations: ACC, American College of Cardiology; AHA, American Heart 
Association; ATP, Adult Treatment Panel; CI, confidence interval; EAS, European 
Atherosclerosis Society; ESC, European Society of Cardiology.
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The third and fourth main dissimilarities are the target 
of the treatment and the drugs to be used. Although the 
published idea is about striking change in these paradigms, 
when a deep analysis is made the differences are not as strik-
ing. Regarding the differences considering CV risk calcula-
tors, it has been argued that they can be mainly explained 
by methodological causes. When considering the target of 
treatment and drugs to be used, probably the dissimilarities 
are more dependent on the interpretation of the evidence 
made by each CPG.
In accordance with ATP III,14 ESC/EAS16,17 and NICE18 
consider that the objectives of the treatment of dyslipidemia 
are analytical values, the so-called, “the lower the better” 
strategy. The main argument by the European CPG in favor of 
the use of low-density lipoprotein cholesterol (LDLc) as the 
target of treatment are the meta-analysis by the Cholesterol 
Treatment Trialists’ (CTT) Collaboration,50,51 estimating a 
direct relationship in which every 40 mg/dL reduction in 
LDLc is associated with a 22% reduction in CV events. The 
new ACC/AHA15 guidelines, based on the fact that any RCT 
has been designed to compare the effect on CV events of 
different analytical parameters to be achieved and the effect 
on different groups of population depending on its CV risk, 
propose that the objective of the treatment has to be just the 
reduction of CV risk itself.52
Some differences exist about which analytical parameter to 
use for target, although all the CPGs recognize the pathophysi-
ological leading paper of LDLc. All of them also recognize 
the higher predictive capacity of apoB and the estimated 
non-high-density lipoprotein cholesterol (nHDLc). For the 
ESC/EAS16,17 as well as for ATP III14 CPG, LDLc is the target, 
based not only on the existing RCT, but also on epidemio-
logical and experimental evidence.53 For ESC/EAS,16,17 when 
considering nHDLc as a target for treatment, more robust 
evidence is necessary, and apoB is not usually as available as 
the other analytical parameters. NICE guidelines18 advocate 
for the use of nHDLc because it includes all lipoproteins with 
atherogenic potential. For those CPG in favor of analytical 
parameters as the target of treatment, the value to be reached 
is always dependent on the global CV risk. A recent extensive 
meta-analysis about optimal strategy for monitoring lipids has 
found an increased prognostic value of composite parameters 
like total cholesterol (Tc)/HDLc ratio (HR [hazard ratio] 1.25; 
95% confidence interval [CI] 1.15–1.35) or nHDLc, compared 
with single parameters such as LDLc.54
For ACC/AHA CPG,15 a practical reason to defend that 
the objective of the treatment is reducing CV risk instead 
of an analytical parameter is that with this strategy the 
 management of dyslipidemia will be easier for the clini-
cian and cheaper for the health system, because periodical 
analytical determinations are not necessary. However, from 
a daily clinical practice point of view, although the intention 
of the analytical determinations is different from a conceptual 
point of view, finally the clinician will probably determine 
the same number of analysis because the new American 
CPG15 also establish the convenience of periodical analysis 
to be sure that the predicted reduction in LDLc in a specific 
patient has been reached, and also to improve the pharmaco-
logical compliance. Finally, we have to read cautiously the 
new American guidelines and their recommendations about 
analytical parameters as target of the treatment: “The Expert 
Panel makes no recommendations for or against specific 
LDLc or nHDLc targets for the primary or secondary pre-
vention of ASCVD (atherosclerotic cardiovascular disease).” 
When grading the recommendation, for ACC/AHA CPG,15 
“No recommendation” means “There is insufficient evidence 
or evidence is unclear or conflicting. Net benefit is unclear. 
Balance of benefits and harms cannot be determined because 
of no evidence, insufficient evidence, unclear evidence, or 
conflicting evidence, and the Work Group thought no recom-
mendation should be”.
The actual situation about dyslipidemia and treatment 
target can be summarized by representing both the ESC/
EAS16,17 and the new American guidelines in two opposite 
positions.15 One position is the so-called “LDLc hypothesis” 
that defends that the benefit of the treatment of dyslipidemia 
is proportional to the value of plasmatic LDLc achieved 
(“The lower the better”). On the contrary, the so-called statin 
pleiotropic effects defends that the benefit obtained in major 
RCTs with pharmacological treatment of dyslipidemia is 
independent of the values of plasmatic LDLc achieved, but 
dependent on the pleiotropic effects of the statins.55 As previ-
ously commented, the first hypothesis is mainly supported by 
a meta-analysis accepted by all the guidelines although with 
different interpretations, that of the CTT collaborators.50 This 
is the position of NICE18 as well as ESC guidelines.16,17,54 On 
the contrary, ACA/AHA guidelines are based on the concept 
of statins as CV-risk lowering drugs due to their pleiotropic 
effects.15,50,52,55 In addition to previously commented rea-
sons in this review, this point of view is supported by the 
absence of reduction of CV events when similar decreases 
of LDLc have been achieved with hypolipemiant drugs 
other than statins.56–58 The benefit obtained in RCTs like the 
Heart Protection Study (HPS) demonstrating the beneficial 
effect of treating patients with acute coronary syndrome 
with LDLc below 100 mg/dL with statins, is well known.59 
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Some authors have also argued that considering LDLc as the 
objective of the treatment can be a strategy to promote the 
use of new drugs.60 The recent publication of IMPROVE-
IT31 has reactivated the debate,58 with no clear accordance in 
the interpretation among the experts and medical societies. 
This RCT has demonstrated that the addition of ezetimibe to 
simvastatin after an acute coronary syndrome achieved 2% 
lower incidence of CV morbidity after lowering LDLc with 
the combination (69.5 vs 53.7 mg/dL), findings consistent 
with the reduction estimated by statins according to the CTT 
meta-analysis.50,51 Although these results seem to reinforce 
the “LDLc hypothesis”, the finding that higher reduction in 
high-sensitive C-reactive protein was also observed with the 
combination can also be interpreted in favor of an increased 
pleiotropic effect.
The fourth main dissimilarity is about the use of hypolipe-
miant drugs other than statins. All the CPG agree that statins 
are the first-line drugs for primary and secondary prevention, 
with striking differences when considering the use of other 
drugs. The ACC/AHA authors,15 taking into account the 
absence of evidence about a beneficial effect on CV morbidity 
or mortality of nonstatin hypolipemiant drugs in the scarce 
number of specific RCT, only consider their use in those 
individuals “…who are candidates for statin treatment but are 
completely intolerant.” The ESC/EAS16,17 always recommends 
the use of statins, and when a high dose is not tolerated or 
LDLc goals are not achieved, the combination with fibrates 
or ezetimibe.61 All the CPG on dyslipidemia were published 
before the publication of the IMPROVE-IT results.32 How-
ever, based on the benefits obtained in subjects with aortic 
stenosis in the Simvastatin and Ezetimibe in Aortic Steno-
sis62 study and in patients with chronic kidney disease in the 
Study of Heart and Renal Protection,63 the authors of ESC/
EAS16,17 CPG consider this drug for treatment in combina-
tion with statins. For these guidelines, bile acid sequestrants 
have also demonstrated their efficacy in RCT with a benefit 
proportional to the LDLc-lowering effect but a lower toler-
ability. On the contrary, although we do not have an official 
opinion by the authors of the ACC/AHA guidelines15 about 
the use of ezetimibe, in a review of the evidence made by a 
group of experts of the US Food and Drug Administration in 
December 2015,64 to consider its authorization for secondary 
prevention in combination with simvastatin, they establish 
that there is a lack of data after the analysis of Ezetimibe 
and Simvastatin in Hypercholesterolemia Enhances Athero-
sclerosis Regression,65 Simvastatin and Ezetimibe in Aortic 
Stenosis,66 and Study of Heart and Renal Protection63 RCTs. 
The different interpretation and derived recommendations 
of the same evidence related to ezetimibe can be explained 
by the fact that the American guidelines15 only analyze the 
impact on CV events, meanwhile the European CPG16,17 also 
consider the effect on LDLc. Finally, NICE guidelines18 have 
an intermediate position concluding that “gemfibrozil to be 
cost effective compared to placebo for secondary prevention 
in men with low HDL cholesterol and low LDL cholesterol, 
based on the VA-HIT (Veterans Affairs High-Density Lipo-
protein Intervention Trial) study.66” However, when compared 
to statins, this effectiveness disappears due to the higher cost 
and higher incidence of secondarisms. NICE18 recommends, 
“Do not routinely offer … except for people with metabolic 
syndrome with high Triglycerides (Tg) and low HDLc even 
if treated with a statin.” For the rest of hypolipemiants data 
are scarcer on efficacy and economic impact, with a higher 
incidence of secondary effects than with statins, justifying the 
general recommendation of “Do not offer.” When considering 
the use of ezetimibe, NICE has published a specific docu-
ment67 recommending its use in nonfamilial heterozygous 
primary hypercholesterolemia when the reduction of CV 
risk is indicated, when analytical objectives are not reached, 
or when statins are not tolerated.
Similarities 
Published commentaries about the new ACC/AHA CPG20 
have usually been to underscore the controversy and dissimi-
larities when compared with other CPG not only in medical 
press but also in the general press, creating an unjustified 
sensationalism evident when a deep read is made in which 
similarities are more than dissimilarities. In any case, in 
modern medicine, new points of view should be not to create 
controversy but rational discussion.68 
Some similarities have been previously mentioned in the 
present review: 1) admitting some limitations, to assure the 
highest level of evidence it is better to have data from RCTs; 
2) because of the limitations of direct application of evidence 
obtained from RCT, it is necessary to share our doubts 
and opinions with the patient as a way to also ameliorate 
accomplishment according to the so-called shared decision 
making11; 3) the reinforcement of the nonpharmacological 
measures as the cornerstone for the treatment of dyslipidemia 
although there is not strong evidence for this recommenda-
tion except with PREDIMED32; 4) management based on 
the idea of CV global risk considering not just one CV risk 
factor but the interaction among all present in each patient; 
and 5) statins as the first-line drugs. 
In reference to the use of multiple CV risk factor strat-
egy, all the CPG recognize that although this strategy has 
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 biological plausibility, there is not any evidence about its 
superiority compared with that based on the treatment of 
individual CV risk factors except that obtained from some 
estimations, as that of Jackson et al.69 This group calculated 
that the number needed to prevent one CV event in five years 
when using three preventive interventions (aspirin, lipid 
lowering, and blood pressure lowering) was only six in the 
very-high-risk group compared with 36 in the low-risk group. 
A recent meta-analysis of the Blood Pressure Lowering 
Treatment Trialists’ Collaboration also established a greater 
impact of blood pressure treatment depending on the global 
CV risk.70 Of course, the Steno experience with diabetic 
people is probably the most demonstrative study about the 
utility of this multifactorial approach.71 
Referred to estimators of individual CV risk, all the 
guidelines are confident in the limitation of the actual cal-
culators, with a poor predictive power, proposing the con-
sideration of other individual variables for clinical decisions 
(Table 3). Although limited predictive capacity of the CV risk 
calculators is critical when evaluating patients in primary 
prevention, it is not the case for secondary prevention, with 
total  accordance among all the CPG in that all people in this 
situation must be treated without estimating CV risk. 
The main concordance, in fact unanimity, among CPG 
on dyslipidemia is about which must be the first-line option 
for pharmacological treatment: statins. All the guidelines 
are also in accordance with that the factor to choose which 
specific statin to be used is its efficacy, classifying them 
in those with high (>40%–50% reduction of pretreatment 
LDLc levels), moderate (30%–40% reduction), and low 
intensity (<30% reduction). Those with high intensity 
have to be used in patients who need a higher individual 
CV risk to be lowered or lower LDLc/nHDLc levels to be 
achieved as a consequence of a higher individual CV risk. 
As shown in Table 4, although there is no absolute concor-
dance when classifying statins by their efficacy, there are 
no huge differences among guidelines. This classification 
is almost identical for ACC/AHA15 and NICE.18 As a small 
difference, the ESC/EAS16,17 represents in a graphic the 
percentual decrease in LDLc expected to be achieved for 
each statin and dose, without a categorical classification. 
The differences in the classification of statins by the three 
Table 3 Risk factors to be considered for the assessment of final individual CV risk in addition to CV calculators based on traditional 
CV risk factors 
Guidelines Other CV risk factors to be considered for the estimation of individual global CV risk
2012 ESC/EAS16,17 •	 Familial prevalence of ASCVD or of major risk factors before 55 years in ♂ and 65 years in ♀
•	 Low socioeconomic status, lack of social support, stress at work and in family life, depression, anxiety, hostility, and the 
type D personality
•	 DM
•	 Low HDLc or apolipoprotein A1
•	 Increased Tg, fibrinogen, homocysteine, apolipoprotein B, and lipoprotein(a), familial hypercholesterolemia or increased 
hs-CRP
•	 Asymptomatic individuals with preclinical evidence of ASCVD (plaques or increased CIMT)
•	 Those with impaired renal function (low estimated glomerular filtration and/or increased microalbuminuria/proteinuria)
•	 Risk may be lower than indicated in those with very high HDLc levels or a family history of longevity
2013 ACC/AHA15 •	 Family history of premature ASCVD with onset <55 years of age in a first-degree male relative or <65 years of age in a 
first-degree female relative
•	 Primary LDLc ≥160 mg/dL or other evidence of genetic hyperlipidemias
•	 hs-CRP ≥2 mg/L
•	 CAC score ≥300 Agatston units or ≥75th percentile for age, sex, and ethnicity
•	 Ankle-brachial index <0.9
•	 Lifetime risk of ASCVD
2014 NICE18 •	 Family history of premature CV disease in medical records
•	 Familial hypercholesterolemia or other inherited disorders of lipid metabolism
•	 Low socioeconomic status
•	 Ethnicity 
•	 Evidence of estimated glomerular filtration rate <60 mL/min/1.73 m2 and/or albuminuria
•	 People with treated HIV, serious mental health problems, taking drugs that can cause dyslipidemia (antipsychotics, 
corticosteroids, or immunosuppressants), systemic inflammatory disorders such as systemic lupus erythematosus, on 
antihypertensives or lipid modifying drugs, recently stopped smoking, body mass index >40 kg/m2
•	 People aged 85 years or older, particularly people who smoke or have raised blood pressure
Abbreviations: ASCVD, atherosclerotic cardiovascular disease; CAC, coronary artery calcium; CIMT, carotid intima/media thickness; DM, diabetes mellitus; HDLc, 
high-density lipoprotein cholesterol; HIV, human immunodeficiency virus; hs-CRP, high-sensitivity C-reactive protein; Tg, triglycerides; CV, cardiovascular; LDLc, low-
density lipoprotein cholesterol; ESC/ EAS, European Society of Cardiology/European Atherosclerosis Society; ACC/AHA, American College of Cardiology/American Heart 
Association; NICE, National Institute for Health and Care Excellence. 
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CPG can be explained because of the different bibliography 
used by each one.50,72–74 NICE18 is the only guideline to also 
consider the effectiveness as a criterion to choose the statin 
to be used, concluding that atorvastatin 20 and 80 mg/day 
are the options to be used in primary and secondary preven-
tion, respectively. 
Referring to the use of statins, all the guidelines, after 
recognizing the paucity of good studies specifically analyzing 
the safety, are also in agreement that main secondary effects 
(myopathy, hepatitis, and diabetes) have a slightly increased 
incidence compared with placebo,48 with a benefit clearly 
higher than the potential harms, with systematic reviews 
finding that the incidence is really unknown, with few cases 
occurring in large-scale RCTs and being encouraging about 
the safety of long-term lipid-lowering therapy.75,76 There is 
also general accordance in the necessity of basal and periodic 
analytical monitoring for the early detection of secundar-
isms. Due to the low incidence of secondarisms, all the CPG 
advocate for monitoring just people at risk or with clinical 
manifestations. The ESC/EAS guidelines16,17 consider the 
identification of population at risk (advanced age, small body 
size, female sex, renal and hepatic dysfunction, perioperative 
periods, hypothyroidism, multisystem disease, and alcohol 
abuse) as the most important measure for the management 
of muscular or hepatic damage. The ACC/AHA15 guideline 
 consider similar risk factors such as multiple or serious 
comorbidities including impaired renal or hepatic function, 
previous statin intolerance or muscle disorders, concomitant 
use of drugs affecting statin metabolism, history of hemor-
rhagic stroke, age >75 years, and Asian ancestry. The three 
CPG state that transaminases should be monitored in all 
patients before starting statins. Referring to CK (creatine 
kinase), the recommendation of the ESC/EAS16,17 CPG is for 
monitoring in all patients. In contrast, for ACC/AHA15 and 
NICE,18 CK needs to be monitored before starting statins just 
in patients with muscular symptoms or at risk for myopathy 
(personal or family history of statin intolerance or muscle 
disease, clinical presentation, or concomitant drug therapy 
that might increase the risk of myopathy). Similar recom-
mendations can be established when considering analytical 
monitoring during the treatment with statins. For ACC/
AHA,15 it is reasonable to measure transaminases and CK 
just if symptoms suggesting hepatotoxicity (jaundice) or 
myotoxicity (pain, tenderness, stiffness, cramping, weak-
ness, or generalized fatigue) arise. After 1 year, it is not 
necessary to monitor transaminases because in the RCT the 
hepatotoxicity usually appears during the first 12 months of 
treatment. For the ESC/EAS,16,17 after initiation of statins, 
CK determination is not necessary except if the existence 
of any muscle symptom, but in contrast to the American 
guidelines,15 transaminases should be monitored 8 weeks 
after the initiation of statin therapy and if the values are lower 
than three times normal value, once per year after that. The 
NICE18 recommendation about transaminases is always a 
basal determination, and then 3 and 12 months after statins 
have been started. All three CPG recommend three times over 
normal values for transmaminases and five times for CK as 
the analytivcal indicators of damage in liver and muscle to 
withdrawal statin treatment.
Another aspect about analytical monitoring is that related 
to lipid profile. It seems that the immediate and logical 
consequence derived from one of the main points of the 
controversy established by the new ACC/AHA guideline15 
about changing the target of treatment (CV risk instead of 
Table 4 Classification of statins depending on their theoretical capacity to reduce LDLc plasmatic levels
Guideline Low intensity Medium intensity High intensity
2013 ACC/AHA
2010 CCT meta-analysis50, 51
<30%
LDLc reduction
30%–49%
LDLc reduction
≥50%
LDLc reduction
Fl 20–40, Lo 20, 
Pr 10–20, Si 10, Pi 1 
Fl 40 bid, Fl XL 80,
Pr 40–80, Lo 40,
Si  20–40,  At 10–20,
Ro 5–10, Pi 2–4
At –80,
Ro 20–40
2012 ESC/EAS
2010 Weng et al meta-analysis72 and 
Mukhtar et al73
20%–30%
LDLc reduction
30%–40%
LDLc reduction
>40%
LDLc reduction
Fl 40, Pr 20–40, 
Lo 10–20, Si 10 
Fl 80, Lo 40–80, 
Si 20, At 10, Pi 1
At 40, Ro 40,
Pi 2–4
2014 NICE18
2003 Law et al meta-analysis74
20%–30% 
LDLc reduction
31%–40%
LDLc reduction
>40% 
LDLc reduction
Pr 40, Fl 40, Pr 20, 
Fl 20, Pr 10, Si 10
Si 40, Si 20, 
At 10, Ro 5 
Si 80, At 40–80, 
Ro 20–40, Ro 10–20
Note: The number after the abbreviation indicates the daily dose in mg.
Abbreviations: At, Atorvastatin; CCT, Cholesterol Treatment Trialists’ Collaboration; Fl, Fluvastatin; Lo, Lovastatin; Pi, Pitavastatin; Pr, Pravastatin; Ro, Rosuvastatin; Si, 
Simvastatin; CV, cardiovascular; LDLc, low-density lipoprotein cholesterol; XL, extended release. 
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analytical parameters) should be  that basal and periodical 
analys of lipid profile are not necessary. But it is not the 
case, at least from a practical daily perspective, because 
this CPG, as the European ones,16–18 recommends basal and 
periodic complete lipid profile determinations. All three 
guidelines establish with a high level of evidence the neces-
sity to determine a complete analytical lipid profile. For the 
ESC/EAS16,17 guidelines, basal lipid profile comprises Tc, 
Tg, HDLc, LDLc, nHDLc, and the Tc/HDLc ratio. NICE18 
and ACC/AHA15 recommend a basal analytical lipid profile 
including Tc, Tg, HDLc, LDLc, and nHDLc. As a difference 
with the other two guidelines for NICE fasting sample is not 
needed.18 After statins are started, all the guidelines recom-
mended periodic analytical profiles, although with differ-
ences about the time intervals. For the ACC/AHA guideline15 
analytical lipid profile should be obtained 4–12 weeks after 
initiation of statin therapy, with controls every 3–12 months 
as clinically indicated. For the ESC/EAS,16,17 the period is 
1–12 weeks after pharmacological treatment initiation, 3-4 
weeks after pharmacological treatment change, and once per 
year after objectives are reached. For NICE18 timing for lipid 
profile determination after hypolipemiant drugs are started 
is 3 months and after that once per year. The exception is for 
acute coronary event; in this case the determination should 
be done 4 weeks after initiation of hypolipemiant treatment. 
All these recommendations are surprising with regard to the 
meta-analysis of Perera et al,54 which demonstrates that lipid 
determination once a year is the most predictive as well as 
effective time period for monitoring. 
It is true that, from a conceptual point of view, the final 
reason for periodic lipid monitoring is quite different among 
CPG. For the European CPG16–18 periodical analytical 
determinations are absolutely necessary because  analytical 
parameters are the target. It is not the case for the American 
CPG,15 which recommends analytical monitoring just to be 
sure that the expected percentage decrease in LDLc compared 
with the basal values has been achieved and to implement the 
therapeutic adherence of the patient. Although recognizing the 
main importance of therapeutic compliance, the ESC/EAS16,17 
guidelines conclude that “A separate issue is the impact of 
regular lipid monitoring in promoting patient adherence to 
lifestyle changes or drug regimens that impact positively on 
their health, as found in a range of studies. It is unclear if 
only the process of monitoring is critical in achieving this or 
a combination of education, regular contact, and adherence 
assessment.”77 NICE18 also considers pharmacological adher-
ence as a cornerstone point for the management of CV risk 
in general but has not detected any significant and effective 
specific strategy to increase the adherence to statins treatment. 
Aspects to be improved upon in the 
actual situation of CPG on lipids 
We have seen in this overview that although the new Ameri-
can guideline on dyslipidemia has proposed some differ-
ent paradigms for the management of dyslipidemia, from 
a clinical point of view, the impact and consequences are 
probably not so important, at least not to modify the daily 
clinical practice, mainly because there are more similarities 
than dissimilarities. And, when common elements exist, it is 
possible to find solutions.
In medicine, because of the relative strength of the evidence 
and constant evolution of knowledge, new points of view 
should be always welcome as an opportunity to improve. When 
considering CPG, it is necessary to be brave to recognize the 
limitations of their recommendations as well as to publically 
defend new concepts, especially when the new proposals hit 
against universally established previous ideas.68 In this con-
text the main input of the 2013 ACC/AHA guideline15 is that 
with the proposal of new paradigms, the reappraisal by all 
the medical community regarding some previously untouch-
able precepts has been activated. It could be criticized for the 
confusion created among clinicians. However, it could also be 
interpreted as a call to action in a globalized and technological 
world among all CPG authors to stop, talk, and discover new 
ways to identify and overcome the actual gaps. It is necessary 
to create consensual new clear and global guidelines to be 
reviewed only when a real novelty has been published with a 
common, predefined, comparable, and universal methodology 
and with the capacity to respect local individualities. As medi-
cal science is not a question of “yes or no”, it is rather always 
a question of “it seems that” “because of this/these reasons/s.”
To help the task of getting a global consensus, we can 
consider the final conclusions in the text of the three CPG on 
the management of dyslipidemia considered at the present 
review as a method for the detection of gaps to be overcome 
(Table 5).16–18,20 With some differences, there are common 
points to begin to discuss and prioritize strategies. When 
considering general/methodological necessities, they can 
be summarized as, 1) need to demonstrate the superiority to 
treat global CV risk instead of individual CV risk factors, 
2) need to demonstrate the beneficial effect of hypolipe-
miant drugs other than statins, 3) need to obtain evidence 
from specific RCTs on nonpharmacological treatment of 
dyslipidemia as well as effectiveness of each kind of treat-
ment. ESC/EAS16,17 guideline are the only ones to comment 
about the necessity of a “systematic comparison of current 
international guidelines to define areas of agreement and the 
reasons for discrepancies.” On the other hand, NICE18 is the 
only CPG to underscore the need for more information about 
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 effectiveness. There is absolute accordance when considering 
the necessity to obtain more information about benefits in 
some population subgroups, especially older people, women, 
and diabetic patients.
In the era of worldwide globalization, it is mandatory to 
adopt consensual solutions for new modern CPG on dys-
lipidemia we need to have clinical guidelines that simplify 
decision-making, based on the best available evidence. 
Meanwhile the results of large trials like IMPROVE-IT,31 
PREDIMED,32 and more recently HOPE 379 can probably 
help to solve some of the actual gaps. In any case, these and 
future high-quality RCTs should not be analyzed from an 
interested point of view creating a war between American 
and European CPG, because there is no doubt that, although 
with important limitations, at this moment RCTs gener-
ate the most robust evidence. However, it is mandatory to 
improve the methodology to obtain evidence, and in the 
actual era where technology is revolutionizing everyday 
life, a methodological change could be feasible. Most 
likely, a real shift in the paradigm of medical investigation 
will be for example the application of big data technology, 
which in the medium term could allow studies of complete 
populations instead of reduced samples sometimes with 
doubtful representation of the reality which needs to be 
studied. In the immediate-term for clinicians, the advice is 
to detect and treat patients at risk applying local specific 
calculators for an early treatment. Considering that the final 
objective of treating dyslipidemia is to avoid CV events, 
use of LDLc or nHDLc has to be promoted whatever the 
intention of the determination, but reinforcing the idea of 
global CV risk. Probably, it is important to maintain the 
analytical monitoring of lipid parameters, because clini-
cians used to work in a daily practice making decisions 
based on numerical thresholds distinguishing healthy and 
ill patients. It is very accommodative because it allows a 
dichotomical, easy, and clear approach to the clinical prob-
lems, but we have to remember that, although operative, 
it is an absolutely artificial approach that creates a false 
security feeling in the adoption of decisions. In any case, 
although new approaches are needed for improvement, an 
indirect indicator that things are being done correctly with 
the actual strategies is the achieved global reduction in the 
incidence of worldwide CV events.78
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Table 5 Gaps to be solved in the future according to the European and the American clinical practice guidelines on dyslipidemia
ACC/AHA 201314 ESC/EAS 201216, 17 NICE 201218
General aspects
Outcomes of RCTs to evaluate alternative 
treatment strategies for ASCVD risk 
reduction. These RCTs may compare titration 
to specific cholesterol or apolipoprotein goals 
versus fixed-dose statin therapy in high-risk 
patients.
Outcomes of RCTs of new lipid-modifying 
agents to determine the incremental ASCVD 
event-reduction benefits when added to 
evidence-based statin therapy.
RCTs to determine whether submaximal statin 
doses, combined with nonstatin therapies, 
reduce ASCVD risk in statin-intolerant 
patients.
There are no recent RCTs of a total risk 
approach to risk assessment; nor risk 
management.
Current systems of grading evidence give most 
weight to RCTs, but many lifestyle measures 
are less amenable to such assessment than 
are drug treatments, which therefore tend to 
receive a higher grade. While the GRADE33 
system attempts to address this issue, more 
debate is needed.
A systematic comparison of current 
international guidelines is needed to define 
areas of agreement and the reasons for 
discrepancies. 
What is the comparative effectiveness of age 
alone and other routinely available risk factors 
versus formal structured multifactorial risk 
assessment for identifying people at high risk of 
developing CVD disease? 
When evaluating cost-effectiveness for statin 
therapy in reducing CVD, is prediction improved 
by the use of a complete meta-analysis dataset 
based on individual patient outcomes rather than 
published outcomes data from individual trials? 
What is the clinical effectiveness and rate of 
adverse events of statin therapy using atorvastatin 
20 mg per day compared with atorvastatin 40 mg 
per day and atorvastatin 80 mg per day in people 
without established CVD?
Specific aspects
Outcomes of RCTs to evaluate statins or 
the primary prevention of ASCVD in adults 
>75 years of age.
Evaluation of the incidence, pathophysiology, 
clinical course, and clinical outcomes of new-
onset diabetes associated with statin therapy.
The young, women, older people, and ethnic 
minorities continue to be underrepresented in 
clinical trials.
What is the effectiveness of statin therapy in 
older people? 
What is the effectiveness of statins or other 
treatments that lower low-density lipoprotein-
cholesterol in people with type 1 diabetes?
Abbreviations: ACC, American College of Cardiology; AHA, American Heart Association; ASCVD, atherosclerotic cardiovascular disease; EAS, European Atherosclerosis 
Society; ESC, European Society of Cardiology; NICE, National Institute for Health and Care Excellence; RCT, randomized clinical trial; CVD, cardio vascular disease; ESC/ 
EAS, European Society of Cardiology.
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